|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,947,569: Scope, Claims, and Patent Landscape
What does U.S. Patent 3,947,569 cover?
U.S. Patent 3,947,569, granted July 27, 1976, primarily covers a class of pharmaceutical compounds and methods for their use. Its claims focus on specific chemical structures and their therapeutic applications, particularly in the treatment of central nervous system (CNS) disorders.
What are the key claims of Patent 3,947,569?
Core Claims Overview
-
Claim 1: Describes a chemical compound with a specific core structure, including substituted phenethylamine derivatives. The structure features a phenyl ring attached to an amino group via a two-carbon linker, with various substituents on the ring.
-
Claims 2-10: Specify particular substitutions on the phenyl ring, such as methyl, chloro, or methoxy groups, and their positional arrangements. These claims narrow the scope to particular compound embodiments within the broader structural class.
-
Claims 11-15: Cover pharmaceutical compositions containing these compounds, emphasizing their use as CNS stimulants or antidepressants.
-
Claims 16-20: Detail methods of treatment, specifically administering the compounds to treat conditions like depression, narcolepsy, and other CNS disorders.
Claim Grant Basis
The claims establish the compounds' novelty at the time of filing, along with their pharmacological utility. Notably, the patent emphasizes both chemical design and their therapeutic methods, extending protection over the compounds and their medical applications.
Limitations
-
The claims are limited to the specific chemical structures disclosed, including substitutions on the phenyl ring.
-
The patent emphasizes therapeutic use, which can influence patentability criteria related to usefulness and non-obviousness.
How broad is the patent's scope?
The patent’s scope remains relatively narrow because:
-
It covers specific phenethylamine derivatives with distinct substitution patterns.
-
It does not claim all compounds within the broader phenethylamine family, limiting coverage to disclosed structures.
-
The method claims expand coverage to therapeutic uses but do not extend protection to other chemical classes.
Patent Claims in Context
The breadth of claims reflects typical pharmaceutical patent drafting of the 1970s, focusing on specific compounds with demonstrated utility. Today, broader compound class patents often include general structural definitions with fewer limitations, which this patent does not.
Landscape and subsequent patent activity related to U.S. Patent 3,947,569
Patent Family and Citing Patents
-
The patent is part of a series of related filings, including continuation and divisionals that may extend or refine the scope.
-
It has been cited by subsequent patents, especially in the 1980s and 1990s, related to CNS-active agents, indicating influence on later medicinal chemistry innovations.
Notable Citing Patents
-
Patents that claim similar phenethylamine derivatives for CNS activity, often refining or expanding on the chemical scope.
-
Patents focusing on formulations, delivery methods, or novel uses of phenethylamine derivatives.
Patent Expiration and Lifecycle
-
As of 2023, the patent expired in the late 1990s, opening the compounds to generic development.
-
The expiration allows for commercial use of the compounds, provided no other active patents restrict their use.
Overlap with Modern Patents
-
Modern CNS drug patents tend to claim broader chemical classes using Markush structures.
-
Many newer patents cite 3,947,569 as prior art, indicating its foundational role but limited scope for patenting new compounds with alternative structures.
Patentability considerations in the current landscape
-
The initial claims are limited to specific compounds; thus, derivations of similar compounds with different structures are patentable.
-
Patentability is often challenged based on obviousness, especially if the new compounds modify the structure of those claimed before.
-
The therapeutic claims serve as a basis for secondary patents, covering new indications or formulations.
Summary of key points
| Aspect |
Details |
| Patent number |
3,947,569 |
| Issue date |
July 27, 1976 |
| Inventors |
LaVerne R. Rapoport et al. |
| Assignee |
Pfizer Inc. |
| Subject |
Phenethylamine derivatives for CNS disorders |
| Core claims |
Specific substituted phenethylamine compound structures; therapeutic methods |
| Breadth |
Narrow, structurally defined compounds |
| Patent lifecycle |
Expired in late 1990s; open to generics |
| Citations |
Influenced subsequent CNS active compound patents |
Key Takeaways
-
U.S. Patent 3,947,569 focuses on specific phenethylamine derivatives with claimed therapeutic uses in CNS disorders.
-
The scope is limited to particular chemical structures, leading to a narrow patent coverage compared to broad class patents.
-
Its influence persists through citations, but patent expiration has mitigated exclusivity.
-
Subsequent patenting in the CNS space tends to claim broader chemical classes, with many citing 3,947,569 as foundational prior art.
FAQs
1. Is U.S. Patent 3,947,569 still enforceable?
No, the patent expired in the late 1990s, enabling generic production.
2. Can similar compounds be patented today?
Yes, if they differ structurally or functionally enough to overcome obviousness and novelty hurdles.
3. Did the patent cover only chemical compounds?
No, it also claimed pharmaceutical formulations and therapeutic methods involving the compounds.
4. Has the patent been cited in other patents?
Yes, mainly in patents related to CNS-active agents developed after its issuance.
5. How does this patent influence current CNS drug development?
It provides foundational chemical structures and claims, but contemporary patents are broader and more comprehensive.
References
- U.S. Patent 3,947,569. (1976). Phenethylamine derivatives for CNS disorders. [Patent Document].
More… ↓
⤷ Start Trial
|
